Experimental nonsteroidal treatment of asthma shows promise

Jul 01, 2010

A new nonsteroidal, anti-inflammatory therapy made from a human protein significantly decreases disease signs of asthma in mice, opening the possibility of a new asthma therapy for patients who do not respond to current steroid treatments. Results of this therapy in an animal model were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

The protein, insulin-like growth factor binding protein-3 (IGFBP-3), uniquely inhibits specific physiological consequences of examined in asthmatic mice, said Youngman Oh, PhD, a study co-author and a professor of at Virginia Commonwealth University, Richmond, Virginia.

IGFBP-3 reportedly targets a key cellular pathway called nuclear factor kappa B, or NF-κB that plays a role in inflammation. The IGFBP-3 protein interferes with its cellular signaling and suppresses NF-κB activity.

"This novel mechanism has never been identified before. Our findings could have major implications not only for asthma but also other inflammatory diseases that NF-κB plays a role in, such as atherosclerosis and rheumatoid arthritis," Oh said.

In asthma, when the airways become inflamed, they become hyperreactive, or overly sensitive, to "triggers," such as dust, smoke and pet dander. This leads to a chain of reactions that elicit an asthma "attack". According to the American Lung Association nearly 23 million people have asthma, of which 9 million are children.

"Anti-inflammatory corticosteroid medicines are an important part of asthma management for many people, but an estimated 20 percent of patients with asthma are resistant to existing steroid medications and there is a critical need for alternate therapies," Oh said.

Using a mouse model, Oh and his colleagues showed that IGFBP-3 production is suppressed in asthma. They measured NF-κB inflammatory activity, using molecular and cellular techniques, and found that treatment with IGFBP-3 blocked NF-κB activity.

The researchers administered IGFBP-3 to the mice by spraying a synthetic form of the into their opened trachea. The treatment "reduced all physiological manifestations of asthma," including airway inflammation and hyperreactivity, Oh said. His research team plans to study IGFBP-3 treatment in asthmatic canine models next.

Explore further: Studies yield mixed findings on high-dose flu vaccine for elders

Related Stories

Antibiotic treatment targets difficult asthma

Dec 17, 2007

Hunter researchers have shown that a commonly available antibiotic can improve the quality of life of patients with difficult asthma, and may also generate significant health care savings.

Recommended for you

Time to move Lyme Disease Awareness Month to April?

10 hours ago

The month of May brings many things, among them Mother's Day, tulips, and Lyme Disease Awareness campaigns. But according to Dr. Richard S. Ostfeld, a disease ecologist at the Cary Institute of Ecosystem ...

An explanation of wild birds' role in avian flu outbreak

12 hours ago

Wild birds are believed to be behind the first major widespread outbreak of bird flu in the United States. The H5N2 virus has cost Midwestern turkey and chicken producers almost 13 million birds since early March, including ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.